Induced neuroprotection by remote ischemic perconditioning as a new paradigm in ischemic stroke at the acute phase, a systematic review by Purroy Garcia, Francisco et al.
RESEARCH ARTICLE Open Access
Induced neuroprotection by remote
ischemic perconditioning as a new
paradigm in ischemic stroke at the acute
phase, a systematic review
Francisco Purroy1,2*† , Cristina García2, Gerard Mauri1,2, Cristina Pereira2, Coral Torres2, Daniel Vazquez-Justes1,2,
Mikel Vicente-Pascual1,2, Ana Vena1,2 and Gloria Arque2*†
Abstract
Background: Remote ischemic conditioning during cerebral ischemia (remote ischemic perconditioning, RIPerC)
refers to the application of several cycles of brief ischemia and reperfusion (I/R) commonly to a limb, and it
represents a new paradigm in neuroprotection with multiple mechanisms of action in ischemic stroke (IS) patients
during acute phase. Some clinical trials just finished, and a few others are still ongoing; gather the current
knowledge and pull it down to influence the present and future studies was the goal of this paper.
Methods: A systematic review of published research papers and/or registered clinical trials since 2000 was
performed.
Results: Nineteen studies were identified and only four studies were completed. All of them have demonstrated
that RIPerC is safe, feasible and well tolerated in IS patients. However, a high heterogeneity of clinical trial
characteristics was observed: five (26.3%) randomized clinical trials (RCTs) included only thrombolytic-treated
patients, three (15.8%) RCTs only thrombectomy-treated patients, and five (26.3%) RCTs required radiological
confirmation of IS. Temporal inclusion criteria vary from 4 h to 48 h. Most of the clinical trials used 4 cycles of RIPerC
in the upper non-affected limb. Interestingly, only three (16.7%) RCTs applied RIPerC during the transportation in
the ambulance. Neuroimaging outputs were the main endpoints when endovascular therapy was applied;
functional outcome is also the main endpoint in large-medium size studies.
Conclusions: This review summarizes the completed and ongoing clinical trials on RIPerC in IS patients, where
RIPerC has been used alone or in combination with recanalization therapies. Ongoing clinical trials will provide new
information on the best RIPerC intervention strategy and potentially improve the functional outcome of IS patients;
definition of new RIPerC strategies would ideally aim at enhancing tissue preservation, promoting neurological
recovery, and stratify patients to improve treatment feasibility.
Keywords: Ischemic stroke, Neuroprotection, Remote ischemic perconditioning, Randomized clinical trials,
Systematic review
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Background
Stroke is one of the leading causes of death and disabil-
ity worldwide [1], with 10.3 million of new strokes and
113 million of disability-adjusted life years per year [2].
Stroke victims face an uncertain future and a life se-
verely affected by disability. The most common type of
stroke is the ischemic stroke (IS), accounting for 87% of
all strokes. It is characterized by the occlusion within an
arterial vessel supplying blood to an area of the brain,
resulting in a corresponding loss of neurological func-
tion. It mainly occurs in elderly patients of both sexes
with often multiple comorbidities (diabetes mellitus,
hypertension, hyperlipidemia, obesity) [3]. Currently, the
only treatments available in the acute phase that have
demonstrated safety and effectiveness are intravenous fi-
brinolytic treatment [4, 5] and mechanical thrombec-
tomy [6]. Unfortunately, even today many patients
cannot benefit from these treatments due to contraindi-
cations, time of evolution of the symptoms or restricted
access to mechanical therapies that are currently only of-
fered in highly sophisticated hospitals. Thus, there is a
need for better and wider therapies to boost patient
adherence.
The effectiveness of neuroprotective therapies has a
great potential to not only increase the benefits of avail-
able reperfusion therapies but also to provide an advis-
able medical procedure for patients who are not eligible
for current treatments. However, translation of most
neuroprotective trials from the bench to the emergency
room has failed so far, they did not demonstrate efficacy
on IS patients, even with promising results in a few pre-
clinical studies [7]. One of the main explanations for this
failure is that the majority of neuroprotective drugs stud-
ied only act on a level of the complex cascade of phenom-
ena that occur in ischemia/reperfusion [7–9]. The
feasibility of neuroprotection in IS is still an unresolved
inquiry. To date, all trials of neuroprotectant compounds
have failed to provide basis and build better trials.
Remote ischemic perconditioning (RIPerC) represents
a new paradigm in neuroprotective therapies [10, 11]
and it has the potential ability to protect the ischemic
brain from injury until reperfusion and, later to protect
the brain from reperfusion injury. RIPerC consists of
short and controlled cycles of ischemia-reperfusion ap-
plied to one limb during the establishment of cerebral is-
chemia [11]. Until now, the underlying mechanisms of
remote ischemic conditioning (RIC) include neurovascu-
lar protection, induced anti-inflammatory action and
neuronal protection against excitotoxicity; paired to-
gether with mitochondrial protection, circulating inflam-
masome activation and/or transcriptional regulation of
neuroprotective pathway [12] (Fig. 1). However, there is
limited data about the clinical translation of RIPerC in
IS patients.
Endogenous cerebral neuroprotection of RIPerC on IS
patients is a new paradigm that aims to enhance the
brain resilience to ischemia and it has the potential to
improve the clinical outcome of affected individuals. For
that, a systematic review of the published articles and
clinical trials on RIPerC applied to IS patients was per-
formed to evaluate and summarize the findings.
Search strategy and selection criteria
A systematic review of prospective cohort studies was
conducted (prehospital-based and hospital-based co-
horts) on acute IS patients under RIPerC and placebo-
arms. Studies published from January 2000 to March
2020 were included. PRISMA recommendations were
followed [13].
Identification, screening and eligibility for included
studies was performed by two reviewers (F.P., G.A.). Bias
analysis was unable to be performed because of the on-
going clinical trials. The search was conducted using the
electronic databases: Pubmed and ClinicalTrials.gov.
Search limits were English language, human and 2000-
current. The search terms were: ‘remote ischemic condi-
tioning’ AND ‘acute ischemic stroke’ OR ‘remote ische-
mic perconditioning’ AND ‘acute ischemic stroke’ OR
‘remote ischemic postconditioning’ AND ‘acute ischemic
stroke’. Prospective human cohort studies that applied
RIPerC in IS patients were included. Studies accepting
inclusion beyond 48 h from the onset of symptoms were
excluded. The last database search was conducted on
September 2019. Following screening of abstracts, full-
text copies of potentially eligible papers were retrieved
and assessed for eligibility.
Results
Electronic database search yielded 32 publications and 27
clinical trials of which 19 studies were finally included in
the systematic literature review (Fig. 2). Among the 31
publications identified on Pubmed search, nine articles
were not related to stroke (29%), four articles applied
chronic PostRIC (13%), three articles were reviews of lit-
erature, three articles described design of the studies or
protocols [14–16], two articles were on subarachnoid
hemorrhage patients, one article was a sub-study and four
articles were not eligible. After applying the inclusion cri-
teria (acute ischemic stroke-AIS patients and application
of remote ischemic perconditioning-RIPerC) and the stud-
ies that accept inclusion beyond 48 h from the onset of
symptoms were exclude; a total of 6 articles were included
and analyzed in the systematic review [16–21], note that 4
out of the 6 papers were previously registered as clinical
trials [18–21]. Twenty-seven randomized clinical trials
(RCTs) were identified on clinicaltrials.gov. Of these
RCTs, 6 (22.2%) applied PostRIC and 4 (14.8%%) were not
considered after inclusion/exclusion criteria were applied.
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Seventeen RCTs were further considered in the present
systematic review (NCT0097596 [21], RESCUE-BRAIN
[15, 22], REVISE-1 [18], rtPA-RIC1 [19], ReCAST-2,
rtPA-RIC, REMOTE-CAT, TRIPCAIS, REVISE-2, RICE
PAC, SERIC-AIS, RICAMIS, RESIST [14], ICARUS,
SERICT-AIS, RIC-SIID, PROTECT I). Table 1 provides a
summary of study design characteristics of the 19 RTCs
on RIPerC application on IS patients.
The first research paper was published by Hougard
et al. in 2014 [21]. Of 443 randomized patients, 247 re-
ceived manual remote ischemic conditioning (mRIC)
during transportation in the ambulance to the hospital.
After adjustment for baseline multimodal magnetic res-
onance imaging (MRI) findings, voxel-wise logistical
analysis showed better radiological evolution of mRIC
treated patients than non-treated patients. However,
there were no significant differences in clinical
neurological outcome between mRIC and control
groups. The paper of Che et al. [19], included only 30
patients treated with recombinant tissue plasminogen
activator (rt-PA). Zhao et al. [18] demonstrated that RIC
is safe in 20 patients who underwent mechanical
thrombectomy. Moreover, England et al. [17] confirmed
the applicability and feasibility of RIC on 13 IS patients
within 24 h after the onset of symptoms. Furthermore,
RIC was associated with changes of plasma biomarkers
related to ischemic tolerance (IT) phenomena, such as
HSP27 and phosphorylated HSP27, whose expression
was significantly different when both arms (control vs.
experimental) of the trial were compared (n = 13) [17].
These four publications included a limited and small
number of recruited subjects [17–19, 21]. In contrast
with previous studies, the multicenter RESCUE-BRAIN
trial [20] was not only focused on IS patients who
Fig. 1 Schematic diagram of the potential and expected neuroprotective effects of remote ischemic perconditioning (RIPerC) on ischemic stroke
at the acute phase. RIPerC refers to the application of several cycles of press and release by an automatic device in a prehospital setting
(ambulance) to an upper non-affected limb. Its clinical application is safe, feasible and well tolerated. The underlying RIPerC mechanisms include
mitochondrial protection, activation of inflammasome, neurovascular protection and specific anti-inflammatory pathway regulation. Ongoing
clinical trials will provide new information on the best RIPerC intervention strategy and reveal underlying neuroprotective mechanisms.
Abbreviations: CBF, cerebral blood flow; TNF-a, tumor necrosis factor alpha; IL-6, interleukin 6; IL-10, interleukin 10; SDF-1a, stromal cell-derived
factor-1; HIF-1a, hypoxia-inducible factor 1-alpha; mTOR, mammalian target of rapamycin; MMPs, matrix metallopeptidases; ROS, reactive
oxygen species
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received or were candidate for revascularization therap-
ies. It included 188 patients with confirmed carotid IS
who underwent magnetic resonance imaging within 6 h
after the onset of symptoms, and 171 (91%) patients
received a recanalization therapy. In RESCUE_BRAIN
trial, RIPerC was applied using an electronic device
on the unaffected lower extremity (4 cycles of 5-min
inflations and 5-min deflations). Brain infarction vol-
ume growth, which was the main outcome, was not
significantly different between the intervention and
control groups. In addition, no significant differences
at 90-days mRS and mortality were observed between
the two groups.
Up to now, there are 19 RCTs identified (where?)
and 17 (89.5%) of them were registered in clinical-
trials.gov. Among them, 14 (73.4%) have been regis-
tered in the last 3 years, 9 (47.4%) have been
developed in China, 9 (47.4%) in Europe and one
(5.3%) in United States. Relating to the estimated
number of enrolled patients on selected RTCs, special
attention must be paid on RICAMIS (n = 1800), RESIST
(n = 1500, 14), SERIC-AIS (n = 912) and REMOTE-CAT
(n = 572).
There is a high variability in the inclusion and exclu-
sion criteria among trials. Five RCTs require radiological
confirmation of acute cerebral infarction despite of the
subsequent treatment received (SERIC-AIS, RIC-SHD,
RICAMIS, RECAST, RESCUE BRAIN). Finally, Danish
RESIST RCTs, Spanish REMOTE-CAT and British
RECAST-2 include patients that met stroke code cri-
teria. Both REMOTE-CAT and RESIST consider the
score of prehospital scales: RACE scale [23] and Prehos-
pital Stroke Score (PreSS), respectively. Only 6 trials
(31.6%) set up an upper age limit as an inclusion criter-
ion. Like in previous RCTs of Hougard et al. [21] and
Che et al. [19], three on-going RCTs (SERICT-AIS,
rtPA-RIC, TRIPCAIS) are focused on the RIC’s role as
an adjuvant treatment of thrombolytic therapy. In con-
trast, REVISE-2, PROTECT I and REVISE-1 [18] in-
cluded patients who underwent thrombectomy.
Fig. 2 PRISMA diagram details the search and selection process of RIPerC systematic review of literature
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Heterogeneity is also evidenced by the number of RIC
cycles applied: 7 (36.8%) RCTs use 5 cycles, one (5.3%)
RCT uses between 3 and 5 cycles, and the rest of the tri-
als use 4 cycles. Thirteen (68.4%) RCTs perform a single
application of RIC. Conversely, SERIC-AIS and RESIST
[14] have planned up to two applications throughout 7
days, like in the finished study of Che et al. [19]; only
REPOST has planned to applied during 4 days [16]. The
application of RIC is located in the non-paretic lower
limb only in one RCT [15], on both upper extremities in
five (26.3%) RCTs, and on upper or lower non-paretic
extremities in one (5.3%) RCT. In most cases, the appli-
cation is restricted to the unaffected upper limb. The ap-
plication of the RIC is manual in 5 (26.3%) RCTs: two
completed RCT [17, 21], REPOST [16], RECAST 2 and
RICE PAC. A simulated control group is only included
in little over half of the considered RCTs.
Certain variability of timing of RIC application is ob-
served within all selected studies. Concretely, in the RE-
SIST trial, temporal inclusion criterion is set at < 4 h
while in RIC-SIID and RICAMIS is extended to 48 h.
RCTs focused on patients treated with intravenous fi-
brinolysis set the maximum time for the evolution of
symptoms to 4.5 h. Instead, among RCTs assessing the
effect of RIC on thrombectomy, the time is set up at 6 h.
The Spanish REMOTE-CAT trial includes patients with
less than 8 h of evolution of symptoms.
Only three RCTs, REMOTE-CAT, RESIST and the
previous published by Hougard et al. [21], initiate the
application of RIC in a prehospital setting, usually in the
ambulance transportation of the patient to the hospital
or stroke care center. Despite the low sample size (n =
15), ICARUS trial aims to reveal the feasibility of RIC
application on thrombectomy candidates who are trans-
ported to comprehensive stroke centers by aircraft.
C, outcome measurements, was there any information
on the size of the final infarct volume, perfusion, recur-
rent stroke?
The high heterogeneity within RCTs is also observed
on the main endpoints (Fig. 3) and outcome measure-
ments. The RCTs yielding the highest number of en-
rolled patients are still on-going (REMOTE-CAT, SERIC
AIS, RESIT and RICAMIS) and all have considered the
clinical endpoint as the main endpoint. In medium size
studies and endovascular therapy related studies, the
main endpoints are infarct volume and/or neuroimaging
outputs. On the first research published paper on the
application of RIC on IS patients, the main endpoint
considered was the neuroimaging outcome [21]. Ische-
mic tolerance-related biomarkers are included in TRIP-
CAIS and RIC-SIID trials. However, other RCTs would
also study biomarkers to detect differential expression
changes. Small-size recruited patients studies demon-
strate whether RIC application is feasible in AIS patients
and AIS patients treated with rt-PA and/or endovascular
therapy [17–19] (Fig. 3).
Discussion
The current systematic review of RIPerC in IS patients
has revealed a noticeable number of trials registered in
clinicaltrials.gov, especially in the last 3 years. Globally, a
broad heterogeneity is observed among RCTs regarding
the number of recruited patients, inclusion criteria,
number of RIPerC applied cycles, location of the appli-
cation, and the main endpoints. Despite the high hetero-
geneity of current studies, they would all contribute to
improve RIPerC effects and mechanisms of action. The
first published evidence of RIPerC in IS patients was
limited to patients that underwent intravenous alteplase
therapy [21]. Moreover, according to new advances in
Fig. 3 Forest plot of included clinical trials and research papers summarized by ischemic stroke (grey dots), rt-PA therapy (black dots) and
endovascular treatment (white dots). Dots height is proportional to estimated enrollment. The analysis included data from 18 studies on four
variables: clinical endpoints, neuroimaging endpoint, biomarker discovery and feasibility
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stroke, five new studies have been focused on patients
treated with endovascular therapy. However, preclinical
data have demonstrated that RIC during acute ischemia
is effective when applied both alone and in combination
with revascularization therapies [24]. For that, results of
the largest RCTs (REMOTE-CAT, SERIC AIS, RESIST
[14] and RICAMIS), which all include IS patients despite
of the acute applied treatment, would be of enormous
interest.
Only one RCT applied RIC manually [21], but one out
of three patients fully complete the cycles. Using an au-
tomated RIC device allows that RIC can be continued
once the patient arrives to the stroke care unit and the
full dose can be administered. For that, most of the
RTCs are currently using automatic devices to apply
RIPerC. Concretely, 14 out of 17 new trials use auto-
matic devices. Another important issue is the number of
cycles and the place of application. Most RIC trials in
Cardiology [25, 26] and the first trials in IS used the
four-cycle protocol, probably due to literature tradition
and preclinical studies. Preconditioning was first demon-
strated in a dog model of myocardial ischemia using a
four-cycle protocol [27]. Afterwards, both RIC before is-
chemia [28] and RIC during ischemia were first docu-
mented using the same protocol [29]. The neutral
clinical results of Hougaard et al. [21] and Pico et al.
[20] trials arise the need to increase the RIC stimulus
and repetitions. Recent studies in preclinical models also
addressed it to optimize the efficacy and optimal dur-
ation of RIPerC [30]. In a rat model of cerebral ischemia,
repeated remote post-conditioning during 14 days after
reperfusion significantly decrease the volume of infarc-
tion [31]. There are some promising experiences in
chronic postconditioning among intracranial stenosis pa-
tients [32] and patients with cerebral small-vessel disease
[33] using five-cycle protocol. Currently, on-going
REMOTE-CAT and RESIST trials use a five-cycle RIC
protocol. Moreover, combination of RIPerC and post-
conditioning during 4 to 7 days is assessed in the RE-
SIST trial [14], ReCAST-2 [17], REPOST [16] and
SERIC-AIS trial. Although, the volume of muscle mass
affects the efficacy of the RIC intervention [34], only
one study proposed RIC application in a leg [20]. It
has been described that one in four IS patients has si-
lent peripheral arterial disease [35], for that it has
suggested that the upper arm would be the best loca-
tion because of safety reasons. One and two-limb
conditioning were equally protective according to pre-
clinical models [30]. At present, how the neuroprotec-
tive stimulus is transferred or its mechanisms of
actions in the brain are not fully understood [36], but
it is known that the translation of the RIC sensory
signal to the brain is crucial [37] and RIC should be
applied in the non-affected arm.
A prehospital administration of RIC in the ambulance
transportation was first proposed by Hougard et al. [21]
and it is established in REMOTE-CAT and RESIST [14]
trials. RIC effects are time-dependent, so early initiation
of RIC is fundamental [38].
Pre-hospital screening scales should be used during
transportation and RIPerC application to correctly
randomize and recruit IS patients. When the Face Arm
Speech Test was used, an increased proportion of pa-
tients with transient symptoms in the intervention group
was observed [21]. It was not clear whether it was a
RIC’s effect or there was a bias in the selection. At
present, both REMOTE-CAT and RESIST [14] trials
have a pre-hospital screening performed by RACE and
PreSS scores, respectively. Patients should be properly
balanced using prehospital stroke scores.
Recently, it has been reported that RIC improves the
clinical evolution of myocardial infarction and it reduces
the final lesion size [25, 39]; but a recent large RCT, with
more than 5000 patients, reported no effects on clinical
outcomes [40]. Cerebral and heart ischemia might differ
on its own characteristics [41], because IS has a variety
of pathogenic mechanisms not present in heart ischemia.
The rupture or erosion of vulnerable plaques in coron-
ary arteries are the most common cause of heart ische-
mia [42], while the embolism from arterial or heart
sources is the main cause of IS [43]. Altogether, we
would anticipate that underlying RIC mechanisms and
clinical outcomes in IS patients will be different and the
expected results of the currents RCTs are promising.
Implications for future research
Currently, there are some on-going randomized clinical
trials that will provide valuable information on RIPerC
in ischemic stroke patients. However, future studies
should carefully examine patient recruitment, RIPerC
application settings, proper outcome measurements and
neuroimaging follow-up protocols. All optimization and
efforts will improve the current knowledge and address
new medical strategies and management of stroke
patients.
According to the RESCUE BRAIN study [20], the ap-
plication of RIC during/after partial or complete reperfu-
sion was futile, and it did not reduce the consequences
of reperfusion injury. So, this might suggest that RIC
should be applied differently. In this line, preclinical data
and results from pilot studies showed that RIC should
be applied as soon as possible, preferable during patient
transportation (prehospital setting, ambulance) to a Hos-
pital, in order to avoid the penumbral tissue recruitment
and extend the time window for further application of
reperfusion therapies. In this context, an early triage and
stratification of the patients using prehospital scales are
essential, and it will also help in the randomization
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process of the clinical trials (REMOTE-CAT,
NCT03375762; RESIST [14]). The accuracy of prehospi-
tal scales is fundamental to identify or confirm a possible
early prehospital treatment effect, like it was suspected
in previous studies [21]. For that, the initial use of pre-
hospital scales is a strong recommendation along RIPerC
application in a prehospital setting and/or as soon as
stroke symptoms are detected.
Automatic devices should be used to ensure com-
pletion of cycles and to document the treatment com-
pliance. Another reason for the futile results of
RESCUE BRAIN [20] study and the study of Hou-
gaard et al. [21] would be that the 4 × 5 cycles of
RIPerC stimulus was not sufficient. To overcome this
issue, increasing up to five cycles and/or the stimulus
repetition twice daily for the first 5 to 7 days would
be an improvement. In the other hand, better selec-
tion of included patients in clinical trials can boost
patient stratification.
Collateral status correlates with stroke severity and
reperfusion outcomes, due to their ability to restrict
the growth of penumbral territory [44]. Although the
underlying mechanisms of RIC are still not fully
known, some recent preclinical studies have showed
an enhancement of collateral circulation [45, 46]. For
that, the role of collaterals is essential in large vessel
occlusion (LVO) patients, whom are also candidates
to undergo mechanical thrombectomy [47, 48] in ad-
mitted hospital, or they are candidates to be trans-
ferred to a Comprehensive Stroke center. Altogether,
LVO patients would be a group of special interest to
study the RIC effects.
Recent published data have highlighted that RIC is safe
and feasible [17–21, 49] similarly to RCTs involving pa-
tients with myocardial infarction [25]. For that, the main
outcomes of the ongoing and future RCTs on RIPerC
have a strong clinical interest. According to stroke treat-
ment academic industry roundtable (STAIR) recommen-
dations [50], 24-h NIHSS, 7-days mRS and 90-days mRS
should be considered to be the standard clinical end-
points in acute stroke trials. Follow-up infarct volume
on brain imaging is also informative, based on preclinical
data that reported an effect of RIC on final brain infarc-
tion volume when it was used alone or in combination
with alteplase [24]. This is recommended by both STAIR
[50] and The Stroke Imaging Research (STIR) group
[47]. More concretely, STIR estimated that sample sizes
based on lesion volumes should be about one fourth of
those based on mRS [51], so the imaging endpoint has
the advantage of requiring smaller sample size. Finally,
the understanding of RIPerC mechanisms and its neuro-
protective role will be a key and animal models studies
surely encourage better refined and translation into
humans for the treatment of ischemic stroke.
Conclusions
The summary of the completed and ongoing RCTs on
RIPerC in IS patients shows that RIC can be initiated
during pre-hospital transport, and it can be used alone
or in combination with current recanalization therapies.
RIPerC has the advantages of simplicity, safety, feasibility
and affordability. The exact time window and the most
effective neuroprotective RIC protocol are still not fully
determined. Stroke preclinical animal models and RIC
research are needed, both will also contribute to define
the RIC molecular effects. Finally, ongoing RCTs will
provide new information on the effect of RIPerC in IS
patients, the optimal RIC protocol application and the
underlying RIPerC mechanisms.
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